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INTRODUCTION
Benign paroxysmal positional vertigo (BPPV) is the most common cause of vertigo, with an incidence between 10.7 and 64.0 cases 
per 100,000 persons, equivalent to a lifetime prevalence of 2.4% [1,2]. The incidence rises with increasing age, and the disease is typ-
ically seen in patients between 50 and 70 years of age, predominantly women [1]. One study estimated that 9% of elderly patients 
undergoing geriatric assessment for nonbalance-related complaints, suffer from BPPV [2].
Benign Paroxysmal Positional Vertigo is characterized by positional vertigo, which is defined as a rotating sensation induced by 
position changes relative to gravity [2]. Usually symptoms are short-lasting (seconds) and emerge when the patient turns their head, 
looks up, or turns over in bed. 
Pathophysiologically, BPPV consists of otoconia from the utricle, which are dislocated into one or several of the semicircular canals 
(SCCs). These dislocated otoconia affect the sensory hair cells during movement via their mass, thereby creating an imbalance of 
signals sent to the central nervous system [3]. Disequilibrium in signals from the vestibular system results in a rotatory sensation (i.e., 
vertigo) [4].
Categorization of BPPV is based on whether the otoconia are floating freely within the endolymph of the SCCs or if otoconia are 
attached to the cupula. Free-floating otoconia are named canalolithiasis, and otoconia attached to the cupula are named cupu-
lolithiasis [3,4]. Furthermore, BPPV can be subcategorized according to the affected SCC(s). Therefore, BPPV may be categorized as 
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anterior-canal BPPV, lateral-canal BPPV, and/or posterior-canal BPPV 
occurring either uni- or bilaterally or as multicanal BPPV and further 
classified as being either canalolithiasis or cupulolithiasis [3, 4-6]. By far, 
posterior-canal BPPV is the most common subtype, including 85-
95% of all BPPV cases, most likely because of its anatomical relation 
to the utricle [6]. Lateral-canal BPPV occurs in 5-15% of all BPPV cases, 
whereas anterior-canal BPPV and multicanal BPPV occurs only in a 
few percentage of BPPV cases [6, 7].
A diagnosis of BPPV requires both subjective symptoms (by means 
of positional vertigo) and objective observation of nystagmus trig-
gered during specific positional tests [6]. The Dix-Hallpike maneuver 
(DH) and the supine roll test (SRT) are two common positional tests 
and, when used in combination, they test all six SCCs of BPPV [3].
Benign Paroxysmal Positional Vertigo often resolves within days 
or weeks without treatment, but early treatment can shorten the 
duration of the disease and improve quality of life [5]. Despite both 
conservative and active treatment, several patients still experience 
persistent BPPV [6].
Several canalith repositioning procedures (CRPs) exist. One of the 
most validated CRPs is the Epley maneuver developed by John Ep-
ley in 1992. This procedure has a reported efficacy rate of 80% when 
treating posterior canalolithiasis BPPV [5].
Lateral-canal BPPV, multicanal BPPV, and cupulolithiasis-type BPPV 
are found to be more difficult to treat; thus, 10-20% of all BPPV cases 
may be challenging to both diagnose and treat [4]. When considering 
the incidence of the disease, the proportion of patients with unre-
solved BPPV who might benefit from better treatments is, therefore, 
potentially quite large. In addition, the recurrence rates of BPPV have 
been reported to be as high as 27% within the first 6 months and 40-
50% after 5 years of follow-up [3]. 
These issues have obviously been a contributing factor to the devel-
opment of the three biaxial chairs for the reposition of BPPV: the Ep-
ley Omniax Rotator [8], the TRV reposition chair [9], and the rather new 
Rotundum positioning chair. Biaxial chairs enable exact positional 
testing and treatment. Because the patient is fixed to the chair, stan-
dardized diagnostic procedures and treatments can be implement-
ed. All chairs allow 360° rotation of the patients in both the horizontal 
and vertical planes. This facilitates both diagnostic procedures and 
repositional maneuvers in patients who can, otherwise, not fully co-
operate. Often, infrared video goggles are used in combination with 
these chairs, adding additional advantages to diagnostics like pupil 
auto tracking, measurement of nystagmus slow-phase velocity, and 
video recording of nystagmus.
Thus far, only a limited number of studies have investigated the use of 
mechanical rotation chairs in the treatment of BPPV, but both diagnos-
tic and therapeutic benefits have been found in previous studies [1,4,10].
The primary objective of this study was to evaluate how successful 
the reposition of BPPV was when treating patients with retractable 
BPPV with the TRV reposition chair. The secondary objectives were 
(1) the number of treatments required for individual subtypes and 
combinations of BPPV and (2) the description of the study popula-
tion according to localization and subtypes of BPPV.
MATERIALS AND METHODS
Patients
A total of 96 patients were initially evaluated and included in this 
study. Following the exclusion of patients, primarily because treat-
ment at some point during the follow-up period deviated from the 
standard treatment protocol, this number was reduced to 81 pa-
tients (Figure 1). All patients were referred to the tertiary Balance & 
Dizziness Centre at the Department of Otolaryngology, Head & Neck 
Surgery and Audiology, Aalborg University Hospital, Denmark with 
intractable BPPV. The patients were classified as being intractable 
because all prior treatments were unsuccessful despite characteristic 
symptomology and diagnostic findings. All patients had undergone 
several (at least five) individual BPPV treatments (manual reposition-
al maneuvers; e.g., standard Epley maneuver, log rolling maneuver, 
Semont maneuver on an examination bed) prior to referral, and pa-
tients had been symptomatic for an average of 16 months. The initial 
treatments were all carried out at regional ENT clinics, which are part 
of the primary care sector in Denmark. Inclusion criteria included 
positional vertigo and a positive result on the DH and/or SRT tests. 
Patients younger than 18 years and those who had previously un-
dergone treatment with a mechanical repositioning chair were ex-
cluded from the study. In addition, patients requiring more than 10 
treatments with the TRV reposition chair were considered resistant to 
TRV reposition chair treatment and classified as “treatment failures.”
Figure 1. Trial profile.
• In combination with video Frenzel googles or Video Nystag-
mography (VNG) equipment, the TRV reposition chair offers 
precise diagnostics of BPPV according to subtype and later-
ality.
• The TRV reposition chair offers effective treatment of pa-
tients with retractable BPPV.
• In general, patients referred with retractable BPPV required 
an average of approximately two treatments.
MAIN POINTS
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Diagnosis
As mentioned, patients were given a diagnosis of BPPV if they ex-
perienced positional vertigo in combination with a positive result 
on the DH and/or SRT tests [11]. Both positional tests were carried 
out with the patients sitting in the TRV reposition chair. All patients 
were fitted with video Frenzel goggles (VF405®, Interacoustics, 
Middelfart, Denmark) during testing, thereby facilitating both pre-
cise and consistent diagnostics. Furthermore, these infrared video 
goggles enabled quantification of nystagmus characteristics with 
measurements of additional parameters such as direction (horizon-
tal and vertical), beats per minute, and average slow-phase velocity 
(a-SPV).
On the basis of nystagmus characteristics observed during positional test-
ing, the patients were divided into different BPPV subcategories (Table 1).
Treatment with the TRV Reposition Chair
The TRV reposition chair enables the repositioning of otoconia 
through different repositioning maneuvers [12]. The patients were as-
signed to different reposition maneuvers based on their BPPV sub-
type(s) and treated with one or more of the maneuvers listed in Table 
2. At every visit, the patients received one treatment with the TRV 
reposition chair. The specific repositional maneuver assigned to the 
individual patient was chosen by the examining physician based on 
expert opinion in order to mimic current clinical practice.
Patients with ipsilateral BPPV of both the posterior and lateral SCCs 
were treated simultaneously with the potentiated Epley maneuver 
because this treatment modality enabled targeting of both SCCs in 
one session with the TRV reposition chair. Patients diagnosed with 
bilateral BPPV initially underwent treatment of their most affected 
side (the side with the highest a-SPV and/or the most symptomatic 
side) during testing with the TRV reposition chair.
The standard Epley maneuver was conducted as described by John Ep-
ley in 1992 [13], but with the patient sitting in the TRV reposition chair. 
The potentiated Epley maneuver was carried out with ten sudden 
decelerations against the rubber stop of the TRV reposition chair in 
every 45° position (five positions) of a 180° turn before returning the 
patient to the upright position. Figure 2 illustrates all positions where 
patients had deceleration treatments applied.
The potentiated Epley maneuver was also performed in a modified 
version with a 225° turn with a starting position 45° ahead of the 
standard DH position. This variant was used for all treatments of the 
cupulolithiasis BPPV subtypes. The Barbeque (BBQ)-roll maneuver 
was performed as described by Thomas Richard Vitton [12]. The deep 
head hanging reposition maneuver was performed ad modum the 
study by Yacovino et al. [14]. All treatments were carried out according 
to the manufacturers’ recommendations.
Figure 2. Illustration of the potentiated Epley maneuver with treatment of a left posterior BPPV. All five positions where decelerations were applied are depicted.
Nystagmus characteristics  Subtypes of BPPV
 Canalolithiasis Cupulolithiasis
Posterior SCC Upbeat nystagmus with rotatory component beating As for canalolithiasis but without latency and also persistent 
 toward the ground (geotropic) during Dix-Hallpike  nystagmus > 1 min. 
 testing. Ipsilateral affection. 
Lateral SCC Geotropic horizontal nystagmus during supine roll  Apogeotropic horizontal nystagmus during supine roll test 
 test in both positions with the highest frequency  in both positions with the highest frequency observed on 
 observed on the affected side. the nonaffected side.
Anterior SCC Downbeat nystagmus with rotatory component  As for canalolithiasis but without latency and also persistent 
 beating away from the ground (apogeotropic) during  nystagmus > 1 min. 
 Dix-Hallpike testing. Contralateral affection. 
SCC: semicircular canal.
Table 1. Nystagmus characteristics defining the different subtypes of BPPV [3, 11]
BPPV subtype Reposition maneuver
Posterior BPPV Standard Epley maneuver
 Potentiated Epley maneuver
Lateral BPPV Barbeque-roll
 Potentiated Epley maneuver
Anterior BPPV Deep head hanging reposition maneuver
Table 2. Types of reposition maneuvers accessible for treatment of individual 
BPPV subtypes
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All patients were scheduled for a minimum of one follow-up after in-
clusion and initial treatment. The patients were continuously given 
a follow-up appointment as long as the treatment(s) was not con-
sidered successful; for example, no positional nystagmus could be 
evoked in the DH and/or SRT positional tests (objective measure), 
and patients did not experience any rotational vertigo during these 
tests (subjective measure). Follow-up visits were scheduled 2-4 weeks 
after the previous treatment. However, to a minor degree, resched-
uling was sometimes necessary because some patients requested 
postponing their follow-up. The interval between follow-ups was, on 
average, 26 days. As a direct consequence of these follow-up con-
ditions, one can conclude that, on average, no early relapses were 
observed 26 days following successful treatment.
Statistical Analysis
The overall treatment effect was described by descriptive statistics. 
Treatment effect differences within BPPV subtypes were analyzed by 
inferential means and expressed in p-values and 95% confidence in-
tervals. This calculation was done with a t-test, and the sensitivity was 
tested with a Wilcoxon rank sum test as data showed not to be fully 
normally distributed.
Results with a p-value <0.05 were considered significant.
Stata/MP 14.0 software was chosen for the processing of data, and 
this processing was carried out with assistance from a certified bio-
statistician. 
RESULTS
Population characteristics are described in Table 3. Most patients had 
a uni- or bilateral sensorineural hearing loss (7% and 57%, respec-
tively). In 38% of patients, the bilateral hearing loss was caused by 
presbycusis. A small minority of patients had other preexisting in-
ner- and/or middle-ear-related comorbidities at the time of referral. 
Five patients (7%) had tinnitus, three (4%) had a unilateral vestibular 
schwannoma, two (3%) had Meniere’s disease, one (1%) had bilateral 
otosclerosis, and one (1%) had previously had vestibular neuritis. In 
patients with multicanal BPPV, the involved SCCs were distributed 
as depicted in Table 4. The overall average number of required treat-
ments with the TRV reposition chair was 2.23 (± 1.66 SD) treatments 
when looking at all BPPV subtypes pooled together.
The mean follow-up time between treatments with the TRV reposi-
tion chair was 25.75 days (± 11.32 SD).
Table 5 shows the average number of treatments required before 
negative positional testing was observed in the different subgroups 
of BPPV.
Patients with affection of one SCC received an average of 1.80 
treatments before a normal positional test was observed together 
with concomitant resolution of symptoms. Patients with multica-
nal BPPV received 3.13 treatments on average before negative po-
sitional testing occurred. This corresponds to a difference of 1.33 
treatments with a p-value of 0.0022 and a confidence interval of 
−2.14 to −0.51.
The total number of affected SCCs averaged 1.37 canals at the first 
treatment, 1.25 canals at the second treatment, and 1.32 canals at 




Total included with BPPV 81*
Age (years), mean (± SD) 61.80 (±15.26)
Sex, n (%) 
Male 27 (36.00)
Female 48 (64.00)
Duration of symptoms pretreatment (months) 
Mean (± SD)  16.03 (± 21.99)
Median 9.00






Multicanal BPPV 24 (32.00)
P-CAN: posterior canalolithiasis; p-CUP: posterior cupulolithiasis; l-CAN: lateral cana-
lolithiasis; l-CUP: lateral cupulolithiasis; a-CAN: anterior canalolithiasis; BPPV: benign 
paroxysmal positional vertigo.
All numbers and calculations are based on 75 patients (excluded and treatment failure 
patients are not included) except the top two values marked with *.
Table 3. Population characteristics
Affected SCCs Number (%)
Posterior bilateral 5 (6.67)
Lateral bilateral 4 (5.33)
Posterior + lateral 13 (17.33)
Anterior + lateral 2 (2.67)
BPPV: Benign Paroxysmal Positional Vertigo; SCC: semicircular canal
Table 4. Distribution of multicanal BPPV






Multicanal BPPV 3.13 (1.70)
P-CAN: posterior canalolithiasis; p-CUP: posterior cupulolithiasis; l-CAN: lateral cana-
lolithiasis; l-CUP: lateral cupulolithiasis; a-CAN: anterior canalolithiasis; BPPV: benign 
paroxysmal positional vertigo.
Table 5. Average number of treatments required for successful treatment 
related to BPPV subtypes
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During the trial period, 17 (22.6%) of the patients experienced either 
dislocation from one SCC to another or debut of BPPV in one of the 
contralateral SCCs.
Following the initial treatment with the TRV reposition chair, 45 
(60%) patients experienced a subjective relief of their symptoms. 
Treatment failure was observed in six patients (7.4%) of the study 
population. All six patients were female, had a mean age of 78.3 
years, and had been symptomatic for an average of 12 months (me-
dian 10.5 months) prior to referral. Five patients had normal inner 
ear findings following MRI of the temporal bone and one patient 
had a normal temporal bone CT scan. One patient was diagnosed 
with Meniere’s disease, one patient had had a cerebral hemorrhage, 
one patient had osteoporosis, and one patient had undergone sur-
gery for otosclerosis prior to referral. No other inner- or middle ear 
comorbidities (or other relevant comorbidities) were observed in 
this group of patients. BPPV subtypes included lateral BPPV (66%) 
with equal distribution of canalo- and cupulolithiasis. In addition, 
one patient (17%) was diagnosed with posterior canalolithiasis and 
one patient (17%) had multicanal BPPV with a combination of pos-
terior and lateral SCC affection.
DISCUSSION 
Primary and Secondary Results
Overall, the rate of successful treatment with the TRV reposition chair 
was 92.4% within a population of retractable BPPV cases. Six patients 
(7.4%) required more than 10 treatments and were therefore classi-
fied as treatment failures. Following general exclusion and omission 
of the treatment failures, 75 patients were further analyzed. These 
patients were distributed as expected according to male/female ratio 
and age when compared with existing studies [5,11,15].
On average, the overall number of required treatments in the TRV 
reposition chair was 2.23 (± 1.66SD) when all BPPV subtypes were 
considered, and all of the analyzed patients were cured from their 
BPPV (however, one must bear in mind that six patients were exclud-
ed from this calculation because of treatment failure before the fi-
nal analyses). Following only one treatment with the TRV reposition 
chair, 60% of the patients reported a relief of symptoms.
On average, patients with either lateral cupulolithiasis or multicanal 
BPPV received 3.13 treatments with the TRV reposition chair before 
negative positional testing was accomplished. This could partly be 
due to the diagnostic procedure when diagnosing lateral canal BPPV 
where the intensity of nystagmus (a-SPV) determines which side 
(left/right) is affected. Because some patients had very analogous 
a-SPV values when comparing the two sides, determination of lat-
erality was sometimes very difficult. Initially, this might have led to 
treatment of the wrong and healthy side, and as a result more treat-
ments had to be carried out before negative positional testing with 
the TRV reposition chair was accomplished. In order to accommodate 
more accurate testing of the lateral SCCs, addition of the “bow and 
lean test” could potentially have added more diagnostic accuracy 
when determining the affected side [2].
Furthermore, a condition with spontaneous nystagmus might dis-
turb the diagnostic procedure of BPPV. It is known that lateral canal 
BPPV is associated with spontaneous nystagmus in up to 66-76% of 
the cases [16]. 
In this study, the BPPV subtype of canalolithiasis generally required 
fewer treatments than that required by the subtype of cupulolithiasis 
(Table 5). This observation fits well with other studies as lateral SCC 
cupulolithiasis, in particular, has been found to be more resistant to 
the treatment [6]. 
We found a significant difference in the average number of treat-
ments required for the single SCC BPPV group versus the multica-
nal BPPV group of 1.33 treatments with a p-value of 0.0022 and a 
confidence interval of −2.14 to −0.51. There is no clear consensus in 
the literature regarding treatment response and prognosis of single 
SCC affection and multi-SCC affection. Some studies found inferior 
response to multi-SCC BPPV [4], whereas others did not find signifi-
cant differences in the prognosis after treatment of single SCC BPPV 
and multi-SCC BPPV [7].
The distribution of BPPV subtypes in this study is not in accor-
dance with that in the existing literature. In this study, there were 
29 (38.67%) patients with posterior BPPV, 18 (24.00%) with lateral 
BPPV, four (5.33%) with anterior BPPV, and 24 (32.00%) with multi-
canal BPPV. Thus, there was a significantly higher proportion of pa-
tients with BPPV in the lateral and anterior SCCs as well as those with 
multicanal BPPV than that in previous studies [5,6,17]. Literature shows 
that these subcategories of BPPV have been found to be more re-
sistant to treatment [4]. In addition, the duration of symptoms was, 
on average, 16.03 (±21.99) months with a median of 9.00 months at 
the time of initial treatment. When considering the natural history 
of BPPV, this is noticeable, because the disease normally resolves it-
self within weeks [5]. One must assume that the patients included in 
this study constitute a group of atypical and very intractable BPPV 
patients. This assumption is based on the fact that these patients all 
had extremely long durations of symptoms and also because of the 
atypical distribution of these patients’ BPPV subtypes. The causes of 
treatment failure in this study can only be speculative but might be 
explained by different variables potentially affecting treatment re-
sults: various inner ear anomalies and otolithic properties. The actual 
angle of the vertical SCCs may vary, the individual SCC may be very 
narrow in general or in specific parts of the canal, and the otoliths 
may also vary in number, size, and density, and may stick together, 
creating a blockage or an otolithic jam.
Prior Studies with Mechanical Chairs
Very few studies have been published on the efficacy of mechanical 
repositional chairs in the treatment of BPPV. The Rotundum chair is 
a very new invention, and currently, no articles have been published 
on its efficacy. Only a few studies have been published on the use of 
the two other chairs. A retrospective study with the TRV reposition 
chair on retractable BPPV cases found results quite similar to those 
in this study. Multicanal and cupulolithiasis-type BPPV required the 
highest number of treatments, and an overall symptom relief of 91.7-
100% was observed after three treatments [4]. Another study, which 
dealt only with posterior BPPV, found that 85.2% required only one 
treatment with the TRV repositional chair. However, this study popu-
lation is not directly comparable, as the previous study excluded all 
other types and combinations of BPPV except posterior canalolithi-
asis [18]. Studies on the 360° maneuver with a rotational chair have 
also been conducted; but these studies are not directly comparable 
with our population because these studies only dealt with patients 
with posterior BPPV [19]. Furthermore, we did not use the 360° ma-
neuver. Previous studies with an automated positioning chair have 
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also proven beneficial [4,20], but the results are not directly compara-
ble as the TRV reposition chair is manually operated. A recent study 
with the TRV reposition chair dealt with dizziness handicap related 
to subtypes of BPPV, but it did not report any comparable effect on 
treatments with the TRV reposition chair [21].
Potential Disadvantages with the Use of A TRV Reposition Chair
There were not many drawbacks with the use of the TRV reposition 
chair. Some patients complained of claustrophobia upon fixation to 
the chair and wearing video Frenzel goggles with vision denied. For 
some patients, this might have led to discontinuation of treatment or 
a loss to follow-up. Furthermore, there was no way to monitor the ac-
tual impact of the decelerations applied by the individual examiner. 
This condition makes the individual treatments susceptible to vary-
ing degrees of both intra- and interexaminer variations. The individu-
al examiner solely determined the number of decelerations inflicted 
and the position of the actual applications. Currently, the choice of 
maneuver is a matter of expert opinion because of a lack of evidence 
on the matter. For instance, a recent Danish study recommended 
only three decelerations applied at the starting and ending positions 
when performing the potentiated Epley maneuver [22]. In our study, 
we used 10 decelerations in all stop positions during the potentiated 
Epley maneuver. The optimal number of decelerations still needs fur-
ther investigation, so that a proper balance between treatment effect 
and induction of contralateral BPPV can be accomplished.
The TRV reposition chair operates only in 45° intervals in the vertical 
plane. Some patients might have atypical inner ear anatomy, with 
the vertical SCCs located at different angles. If this is the case, pa-
tients may not be treated successfully with this chair.
Adding an infrared video goggle to the examination in the TRV repo-
sition chair improves tracking of eye movements. For inexperienced 
examiners, a drawback to this might be that overinterpretation of 
minor (nonpathological) eye movements might occur. This will po-
tentially lead to over diagnosis and redundant treatments.
In this study, 22.6% of patients experienced either dislocation from 
one SCC to another SCC ipsilaterally, BPPV relapse, or BPPV in one 
or more of the contralateral SCCs. This relatively large proportion of 
recurrent disease is, to some extent, expected. This is primarily be-
cause dislocation from the posterior to the lateral SCC and vice versa 
is seen in 6% of all BPPV cases during standard repositioning maneu-
vers [6]. In addition, relapses are reported as high as 27% during the 
first month following successful treatment [3]. Adding kinetic energy 
during reposition maneuvers might explain why so many patients 
develop contralateral BPPV following treatment.
Potential Disadvantages of Study Design
A total of 96 patients were initially included for this study, but 15 pa-
tients were excluded. This is a major concern when considering the 
dataset, as these patients comprise almost 16% of the entire study 
population. One can only speculate about the reasons for this high 
degree of loss to follow-up. Three patients did not have BPPV and 
were therefore excluded. Ten patients were excluded because devia-
tion(s) from the treatment protocol of the project was/were deemed 
necessary at some point during the follow-up period. Lastly, two 
patients discontinued their treatment because of discomfort in the 
TRV reposition chair. Especially with the group of patients where a 
deviation from standard treatment protocol was deemed necessary, 
one must consider if selection bias may have affected the results. 
Did these patients have unknown pathologies or special properties 
within their inner ears that made them particularly resistant to stan-
dard treatments? However, in general, all of the excluded patients 
had multicanal BPPV with alternating sides of affection. Overall, the 
excluded patients were comparable with the analyzed population 
(gender, length of pretreatment vertigo, number of treatments, BPPV 
subtypes), except their mean ages. Within the group of treatment 
failures, the mean age was 78.3 years compared with a mean age of 
61.8 years within the group of analyzed patients. This group also ex-
clusively consisted of women, and most of these patients had lateral 
canal BPPV. Whether these characteristics might have influenced or 
contributed to the severity and retractability of their BPPV remains 
speculative.
The study was conducted as a prospective observational study. For 
ethical reasons, it was not possible to avoid treatment of one group 
of patients, and as a direct consequence, the study was carried out 
without any control group. Furthermore, if a control group should 
have been included in this study, a randomization between treat-
ments with or without the TRV reposition chair should have taken 
place at the time of inclusion. As our study population had already 
undergone several unsuccessful manual reposition attempts at the 
time of referral, it was not considered appropriate with a randomiza-
tion that included treatments already proven unsuccessful. However, 
a control group is preferable when the target measure is a treatment 
effect. 
Potential Advantages with the Use of A TRV Reposition Chair
There were several benefits of using the TRV reposition chair for the 
diagnostics as well as the treatment of BPPV. First, patients did not 
have to follow complicated instructions. Fixation of the patient to the 
chair allows 360° rotation of the patient in both the horizontal and 
vertical planes, regardless of compromised patient compliance. This 
enabled precise and consistent reposition maneuvers for all treat-
ments. In addition, fitting patients with video Frenzel goggles with 
accompanying software enabled visualization and quantification of 
any nystagmus elicited during the positional testing. This was par-
ticularly helpful when patients experienced multiple SCC affection, 
especially lateral SCC affection, where the nystagmus intensity helps 
to determine the side of pathology [3].
The reasons why the TRV reposition chair enabled treatment of re-
tractable BPPV with excellent results are probably numerous. The 
precise and consistent movements of endolymph (and otoconia) 
within the specific planes of the SCCs made possible by the chair and 
the simultaneous use of video Frenzel goggles are two likely expla-
nations. In addition, it is plausible to assume that the TRV reposition 
chair applies rotational energy to the endolymph during the BBQ roll 
maneuver, as the patient during this maneuver is kept in constant 
rotation. Kinetic energy is probably also applied to the otoconia via 
steep decelerations during the potentiated Epley maneuver. Over-
all, most of our patients underwent treatments where kinetic forces 
were applied to add additional effect to the standard treatments the 
patients had already received prior to referral.
The TRV reposition chair also facilitates standardization and align-
ment of especially the diagnostic part. The chair has fixed intervals 
of 45° rotations in the vertical plane enabling precise and repetitive 
positioning of the patient independent of the examiner. Therefore, 
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especially in terms of diagnostics, the TRV reposition chair has a low 
degree of both intra- and interexaminer variations. In treatments 
with the TRV reposition chair, the actual positioning of the patient 
during reposition is also standardized and reproducible and there-
fore without any significant intra- and interexaminer variations.
Potential Advantages of Study Design
The natural history of BPPV usually includes spontaneous resolution 
of the disease within a few weeks following the onset of symptoms 
[5]. Therefore, we consider the observed effect of treatment(s) with 
the TRV reposition chair as being reliable and not just the result of 
random spontaneous relapses. On average, patients had been symp-
tomatic for 16 months. Another significant strength of the design is 
the prospective course of the study and the relatively short intervals 
between appointments and repositioning maneuvers. All patients 
were treated with the TRV reposition chair, with a mean follow-up 
time of 25.75 days (±11.32 SD) between treatments. It was decided 
at project planning that an optimal follow-up time would be 2-4 
weeks to obtain a reliable treatment effect. Wider intervals could be 
disturbed by relapses, thus underestimating the effect. The optimal 
follow-up time is disputed. However, a systematic review found sev-
eral studies that apply 4 weeks between treatments [4]. During repo-
sitioning, in theory, otoconia are removed from the SCC(s) during 
the repositioning maneuver itself. This speaks against long follow-up 
intervals, when the effect of reposition is to be investigated, as long 
intervals may lead to underestimation owing to the relapsing nature 
of BPPV.
CONCLUSION
We conclude that the TRV reposition chair is an effective means of 
treating patients with retractable BPPV. However, 7.6% of patients ex-
perienced treatment failure. The TRV reposition chair is proved to be 
an excellent diagnostic tool for diagnosing BPPV. It enables precise 
diagnostics in subtypes of both canalo- and cupulolithiasis as well 
as to what SCC(s) is(are) affected uni- and/or bilaterally. Thus far, only 
a few studies have been published on the use of the TRV reposition 
chair in the treatment and diagnosis of retractable BPPV. Therefore, 
further studies are important for the future implementation and de-
velopment of this promising treatment modality.
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